Monopar Therapeutics (MNPR) Assets Average (2018 - 2020)
Historic Assets Average for Monopar Therapeutics (MNPR) over the last 3 years, with Q3 2020 value amounting to $15.5 million.
- Monopar Therapeutics' Assets Average rose 18923.37% to $15.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $15.5 million, marking a year-over-year increase of 18923.37%. This contributed to the annual value of $10.3 million for FY2019, which is 1983.14% up from last year.
- Per Monopar Therapeutics' latest filing, its Assets Average stood at $15.5 million for Q3 2020, which was up 18923.37% from $12.8 million recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Assets Average ranged from a high of $15.5 million in Q3 2020 and a low of $5.4 million during Q3 2019
- Over the past 3 years, Monopar Therapeutics' median Assets Average value was $8.8 million (recorded in 2018), while the average stood at $9.4 million.
- Per our database at Business Quant, Monopar Therapeutics' Assets Average plummeted by 3447.16% in 2019 and then surged by 18923.37% in 2020.
- Monopar Therapeutics' Assets Average (Quarter) stood at $7.6 million in 2018, then increased by 21.41% to $9.2 million in 2019, then soared by 67.7% to $15.5 million in 2020.
- Its Assets Average was $15.5 million in Q3 2020, compared to $12.8 million in Q2 2020 and $13.1 million in Q1 2020.